Skip to main content

Advertisement

Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Transplantation of mesenchymal stem cells ameliorates secondary osteoporosis through interleukin-17-impaired functions of recipient bone marrow mesenchymal stem cells in MRL/lpr mice

Fig. 3

Systemic human MSC transplantation recovers IL-17-impaired recipient BMMSC-mediated osteogenesis in the bone marrow of MRL/lpr mice. a A schema of the osteogenic capacity of recipient bone marrow mesenchymal stem cells (BMMSCs). Recipient BMMSCs were induced by ascorbic acid (AA) and inorganic phosphate (Pi), and treated with or without recipient BMC-derived conditioned medium (CM) in the presence of anti-mouse IL-17 antibody (Anti-IL-17 Ab), control antibody for anti-mouse IL-17 antibody (Cont Ab) or recombinant mouse IL-17 (IL-17). bd Osteogenic assay by Alizarin Red staining at 4 weeks after osteogenic induction. n=5 for all groups. Values are shown as means ± SD. **P < 0.01, ***P < 0.005. # P < 0.05, ## P < 0.01, ### P < 0.005, versus MSC-WT treated with CM-MRL/lpr in the presence of Cont Ab. ††† P < 0.005, versus MSC-MRL/lpr. CM-hBMMSC conditioned medium of BMC-hBMMSC culture under stimulation with anti-CD3 and CD28 antibodies; CM-MRL/lpr, conditioned medium of BMC-MRL/lpr culture under stimulation with anti-CD3 and CD28 antibodies; CM-SHED conditioned medium of BMC-SHED culture under stimulation with anti-CD3 and CD28 antibodies; MSC-WT BMMSCs isolated from wild-type C57BL/6 mice

Back to article page